Genus plc (GENSF)
USD 25.1
(0.0%)
USD 25.1
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 147.7 Million USD | -27.33% |
| 2023 | 237.1 Million USD | 26.17% |
| 2022 | 187.92 Million USD | -13.85% |
| 2021 | 218.13 Million USD | 20.18% |
| 2020 | 181.5 Million USD | 14.64% |
| 2019 | 158.32 Million USD | -4.83% |
| 2018 | 166.35 Million GBP | 13.53% |
| 2017 | 146.52 Million GBP | 85.77% |
| 2016 | 78.87 Million GBP | -15.65% |
| 2015 | 93.5 Million GBP | 9.36% |
| 2014 | 85.5 Million GBP | -1.95% |
| 2013 | 87.2 Million GBP | 11.65% |
| 2012 | 78.1 Million GBP | -47.93% |
| 2011 | 150 Million GBP | 10.21% |
| 2010 | 136.1 Million GBP | 10.56% |
| 2009 | 123.1 Million GBP | 10.6% |
| 2008 | 111.3 Million GBP | 5.2% |
| 2007 | 105.8 Million GBP | 158.42% |
| 2006 | -181.1 Million GBP | -204.71% |
| 2005 | 172.94 Million GBP | 0.04% |
| 2004 | 172.87 Million GBP | 8.64% |
| 2003 | 159.13 Million GBP | 7.32% |
| 2002 | 148.27 Million GBP | -3.51% |
| 2001 | 153.66 Million GBP | 20.38% |
| 2000 | 127.64 Million GBP | 131.53% |
| 1999 | 55.13 Million GBP | 17.92% |
| 1998 | 46.75 Million GBP | -2.52% |
| 1997 | 47.95 Million GBP | 2.62% |
| 1996 | 46.73 Million GBP | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 153.55 Million GBP | -58.66% |
| 2024 Q2 | 366.87 Million USD | 138.93% |
| 2024 FY | 778.17 Million USD | 228.2% |
| 2024 Q4 | 413.8 Million USD | 0.0% |
| 2023 Q2 | 378.42 Million USD | 129.9% |
| 2023 Q1 | 164.6 Million GBP | 298.55% |
| 2023 Q3 | 61.05 Million GBP | -83.87% |
| 2023 Q4 | 371.39 Million USD | 508.35% |
| 2023 FY | 237.1 Million USD | 26.17% |
| 2022 Q1 | 127.1 Million GBP | 241.21% |
| 2022 FY | 187.92 Million USD | -13.85% |
| 2022 Q3 | 41.3 Million GBP | -67.51% |
| 2022 Q2 | 127.1 Million USD | 0.0% |
| 2022 Q4 | 41.3 Million USD | 0.0% |
| 2021 FY | 218.13 Million USD | 20.18% |
| 2021 Q2 | 123.1 Million USD | 0.0% |
| 2021 Q1 | 123.1 Million GBP | 219.33% |
| 2021 Q4 | 37.25 Million USD | 0.0% |
| 2021 Q3 | 37.25 Million GBP | -69.74% |
| 2020 Q2 | 118.89 Million USD | 0.0% |
| 2020 Q4 | 38.55 Million USD | 0.0% |
| 2020 FY | 181.5 Million USD | 14.64% |
| 2020 Q1 | 118.89 Million GBP | 985.84% |
| 2020 Q3 | 38.55 Million GBP | -67.58% |
| 2019 Q1 | 97.5 Million GBP | 4775.0% |
| 2019 Q3 | 10.95 Million GBP | -88.77% |
| 2019 FY | 158.32 Million USD | -4.83% |
| 2019 Q4 | 10.95 Million USD | 0.0% |
| 2019 Q2 | 97.5 Million GBP | 0.0% |
| 2018 Q1 | 87.64 Million GBP | 313.44% |
| 2018 Q2 | 87.64 Million GBP | 0.0% |
| 2018 FY | 166.35 Million GBP | 13.53% |
| 2018 Q3 | 2 Million GBP | -97.72% |
| 2018 Q4 | 2 Million GBP | 0.0% |
| 2017 Q4 | 21.2 Million GBP | 0.0% |
| 2017 FY | 146.52 Million GBP | 85.77% |
| 2017 Q1 | 85.2 Million GBP | 94.3% |
| 2017 Q2 | 85.2 Million GBP | 0.0% |
| 2017 Q3 | 21.2 Million GBP | -75.12% |
| 2016 FY | 78.87 Million GBP | -15.65% |
| 2016 Q4 | 43.85 Million GBP | 0.0% |
| 2016 Q3 | 43.85 Million GBP | -49.63% |
| 2016 Q2 | 87.05 Million GBP | 0.0% |
| 2016 Q1 | 87.05 Million GBP | -3.39% |
| 2015 FY | 93.5 Million GBP | 9.36% |
| 2015 Q3 | 90.1 Million GBP | 6.75% |
| 2015 Q1 | 84.4 Million GBP | 2382.35% |
| 2015 Q2 | 84.4 Million GBP | 0.0% |
| 2015 Q4 | 90.1 Million GBP | 0.0% |
| 2014 Q4 | 3.4 Million GBP | 0.0% |
| 2014 FY | 85.5 Million GBP | -1.95% |
| 2014 Q3 | 3.4 Million GBP | 580.0% |
| 2014 Q2 | 500 Thousand GBP | 0.0% |
| 2014 Q1 | 500 Thousand GBP | -98.08% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 FY | 87.2 Million GBP | 11.65% |
| 2013 Q4 | 26.09 Million GBP | 0.0% |
| 2013 Q3 | 26.09 Million GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | 78.1 Million GBP | -47.93% |
| 2011 FY | 150 Million GBP | 10.21% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 FY | 136.1 Million GBP | 10.56% |
| 2010 Q2 | - GBP | 0.0% |
| 2009 FY | 123.1 Million GBP | 10.6% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | 111.3 Million GBP | 5.2% |
| 2007 Q2 | - GBP | 0.0% |
| 2007 FY | 105.8 Million GBP | 158.42% |
| 2006 FY | -181.1 Million GBP | -204.71% |
| 2006 Q1 | - GBP | 0.0% |
| 2005 FY | 172.94 Million GBP | 0.04% |
| 2005 Q1 | - GBP | 0.0% |
| 2004 Q1 | - GBP | 0.0% |
| 2004 FY | 172.87 Million GBP | 8.64% |
| 2003 FY | 159.13 Million GBP | 7.32% |
| 2002 FY | 148.27 Million GBP | -3.51% |
| 2001 FY | 153.66 Million GBP | 20.38% |
| 2000 FY | 127.64 Million GBP | 131.53% |
| 1999 FY | 55.13 Million GBP | 17.92% |
| 1998 FY | 46.75 Million GBP | -2.52% |
| 1997 FY | 47.95 Million GBP | 2.62% |
| 1996 FY | 46.73 Million GBP | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -10960.1% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2829.368% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -399.78% |
| Nascent Biotech, Inc. | 2.22 Million USD | -6523.678% |
| Rebus Holdings, Inc. | 664 Thousand USD | -22143.976% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -296.45% |
| Qrons Inc. | 643.67 Thousand USD | -22846.291% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -37813.986% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -157.138% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -35449.33% |
| Skye Bioscience, Inc. | 13.54 Million USD | -990.234% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -70.191% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2903.306% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -56333.064% |
| SQZ Biotechnologies Company | 85.61 Million USD | -72.508% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -4964.75% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -9734.217% |
| Mesoblast Limited | 5.9 Million USD | -2402.542% |
| Marizyme, Inc. | 19.23 Million USD | -667.678% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1582.379% |
| Pharming Group N.V. | 225.49 Million USD | 34.498% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -7109.432% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -10909.694% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1671.196% |
| ContraFect Corporation | 56.88 Million USD | -159.628% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -3250.215% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -9888.152% |
| IMV Inc. | 37.7 Million USD | -291.681% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -5193.23% |
| MultiCell Technologies, Inc. | 567.42 USD | -26030001.16% |
| ONE Bio Corp. | 6.44 Million USD | -2192.093% |
| Accustem Sciences Inc. | 3.74 Million USD | -3842.431% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -71.854% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -27665.141% |
| Q BioMed Inc. | 3.43 Million USD | -4197.818% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -497.613% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -5521.266% |
| Biomind Labs Inc. | 994.18 Thousand USD | -14756.435% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -48.696% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -8293.581% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -2098.566% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -7822.247% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 590900.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -822.535% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -7948.63% |
| GB Sciences, Inc. | 1.42 Million USD | -10297.681% |
| Alpha Cognition Inc. | 9.7 Million USD | -1421.802% |
| HST Global, Inc. | 140.9 Thousand USD | -104720.91% |
| CSL Limited | 3.44 Billion USD | 95.718% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -13029.939% |
| Halberd Corporation | 74.84 Thousand USD | -197249.082% |
| Enzolytics Inc. | 2.17 Million USD | -6676.762% |
| Agentix Corp. | 1.37 Million USD | -10667.221% |
| Resverlogix Corp. | 12.71 Million USD | -1061.894% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -3945.792% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 90.369% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -14047.51% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -6041.541% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -9251.919% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -4237.765% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1920.447% |
| Zenith Capital Corp. | 8.94 Million USD | -1551.571% |
| Genscript Biotech Corporation | 825.34 Million USD | 82.104% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -847727.335% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -5915.517% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -86017.93% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -7589.08% |
| Kadimastem Ltd | 2.41 Million USD | -6028.346% |
| Helix BioMedix, Inc. | 1.97 Million USD | -7389.729% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1259.161% |
| BioStem Technologies, Inc. | 22.97 Million USD | -542.878% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -81284.136% |
| LadRx Corporation | 3.81 Million USD | -3774.819% |
| Cell Source, Inc. | 4.32 Million USD | -3314.756% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -15893.33% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -15893.33% |
| NovAccess Global Inc. | 2.46 Million USD | -5887.609% |
| Affymax, Inc. | 39.38 Million USD | -275.006% |
| Itoco Inc. | 919.14 Thousand USD | -15969.317% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -3384.794% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -13099.285% |
| Mobile Lads Corp. | 554.54 Thousand USD | -26534.4% |
| CytoDyn Inc. | 18.05 Million USD | -717.92% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -586733.009% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -67012.569% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -10302.932% |
| SYBLEU INC | 160.87 Thousand USD | -91709.841% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -8031.827% |
| International Stem Cell Corporation | 5.27 Million USD | -2702.125% |
| Bioxytran, Inc. | 3.82 Million USD | -3766.343% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -280474.446% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -725948.272% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -307.269% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -9028.554% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -19972.435% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -4647.67% |
| Neutra Corp. | 243.82 Thousand USD | -60477.227% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -746.079% |
| PureTech Health plc | 144.59 Million USD | -2.146% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -620.843% |
| IXICO plc | 4.7 Million USD | -3037.88% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1578.981% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -25.437% |
| CSL Limited | 3.89 Billion USD | 96.206% |
| Cellectis S.A. | 97.32 Million USD | -51.767% |